| Symbol | GRFS |
|---|---|
| Name | GRIFOLS SA |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 08022 Spain Calle Jesus y Maria 6 |
| Telephone | [34] 935 710 500 |
| Fax | — |
| — | |
| Website | http://www.grifols.com |
| Incorporation | ES |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ;Pink Limited |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001438569 |
| Description | As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firms bioscience business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 15% of revenue following the Novartis and Hologic deals. Additional info from NASDAQ: |
2026-05-11 15:30
Grifols Communoication - Grifols: A highly distinct and unique position in the plasma derived therapeutics industry
Read more
2026-05-07 15:38
Grifols communication - Grifols increases Q1 2026 revenues by 3.3% to €1.7billion, and net profit 21.9% to €73 million
Read more
2026-04-30 09:59
Grifols Communication - Grifols to Hold Earnings Call for Q1 2026 Financial Results on May 7, 2026
Read more
2026-04-24 06:56
Grifols Communication - Grifols streamlines its global plasma network with the closure of 29 donation centers in the U.S.
Read more
2026-04-14 11:10
Grifols Communication - Grifols has concluded today a successful refinancing of its 2027 debt maturities
Read more
2026-04-13 06:31
Grifols Communication - Grifols announces €500m redemption of 7.5% 2030 bonds to further optimize its capital structure
Read more
2026-04-01 18:07
Grifols Communication - Grifols fully refinances all 2027 maturities following a significantly upsized €3bn Term Loan B
Read more
2026-03-24 21:23
Grifols Communication - Grifols prepares IPO of its U.S. Biopharma business
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07582432 | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex … | Phase3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Recruiting | 2026-04-23 | 2028-08-31 | ClinicalTrials.gov |
| NCT07582432 | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex … | Phase3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Recruiting | 2026-04-23 | 2028-08-31 | ClinicalTrials.gov |
| NCT07555483 | A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Differen… | Phase3 | Alpha 1 Antitrypsin Deficiency | Not_Yet_Recruiting | 2026-04-21 | 2026-09-29 | ClinicalTrials.gov |
| NCT07555483 | A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Differen… | Phase3 | Alpha 1 Antitrypsin Deficiency | Not_Yet_Recruiting | 2026-04-21 | 2026-09-29 | ClinicalTrials.gov |
| NCT07540221 | A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C… | Phase3 | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Recruiting | 2026-04-02 | 2027-12-31 | ClinicalTrials.gov |
| NCT07540221 | A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C… | Phase3 | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Recruiting | 2026-04-02 | 2027-12-31 | ClinicalTrials.gov |
| NCT07264517 | Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants … | Phase2 | Dry Eye Disease | Recruiting | 2025-11-03 | 2026-11-14 | ClinicalTrials.gov |
| NCT07264517 | Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants … | Phase2 | Dry Eye Disease | Recruiting | 2025-11-03 | 2026-11-14 | ClinicalTrials.gov |
| NCT07152834 | Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction | — | Alpha 1-antitrypsin Deficiency (AATD) | Recruiting | 2025-08-06 | 2026-01-05 | ClinicalTrials.gov |
| NCT07152834 | Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction | — | Alpha 1-antitrypsin Deficiency (AATD) | Recruiting | 2025-08-06 | 2026-01-05 | ClinicalTrials.gov |
| NCT06812390 | Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites | Phase2 | Cirrhosis | Recruiting | 2025-02-28 | 2027-03-01 | ClinicalTrials.gov |
| NCT06812390 | Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites | Phase2 | Cirrhosis | Recruiting | 2025-02-28 | 2027-03-01 | ClinicalTrials.gov |
| NCT04636268 | FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophyla… | Phase3 | Congenital Afibrinogenemia | Withdrawn | 2023-12-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT04636268 | FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophyla… | Phase3 | Congenital Afibrinogenemia | Withdrawn | 2023-12-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT06052176 | Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement | Phase2 | Cirrhosis | Recruiting | 2023-11-02 | 2026-12-01 | ClinicalTrials.gov |
| NCT06052176 | Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement | Phase2 | Cirrhosis | Recruiting | 2023-11-02 | 2026-12-01 | ClinicalTrials.gov |
| NCT05794165 | Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-R… | Phase2 | Trauma Injury | Enrolling_By_Invitation | 2023-09-27 | 2027-03-01 | ClinicalTrials.gov |
| NCT05794165 | Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-R… | Phase2 | Trauma Injury | Enrolling_By_Invitation | 2023-09-27 | 2027-03-01 | ClinicalTrials.gov |
| NCT05382650 | Survey of Human Rabies Immune Globulin Safety in Children | — | Rabies | Terminated | 2023-02-22 | 2025-10-15 | ClinicalTrials.gov |
| NCT05382650 | Survey of Human Rabies Immune Globulin Safety in Children | — | Rabies | Terminated | 2023-02-22 | 2025-10-15 | ClinicalTrials.gov |
| NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treat… | Phase3 | Hypogammaglobulinemia | Recruiting | 2022-12-26 | 2026-06-01 | ClinicalTrials.gov |
| NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treat… | Phase3 | Hypogammaglobulinemia | Recruiting | 2022-12-26 | 2026-06-01 | ClinicalTrials.gov |
| NCT04450654 | Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necroti… | Phase2 | Immune-Mediated Necrotizing Myopathy | Withdrawn | 2022-05-01 | 2022-07-25 | ClinicalTrials.gov |
| NCT04450654 | Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necroti… | Phase2 | Immune-Mediated Necrotizing Myopathy | Withdrawn | 2022-05-01 | 2022-07-25 | ClinicalTrials.gov |
| NCT05094856 | Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Sh… | — | Septic Shock | Completed | 2022-02-23 | 2023-03-16 | ClinicalTrials.gov |
| NCT05094856 | Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Sh… | — | Septic Shock | Completed | 2022-02-23 | 2023-03-16 | ClinicalTrials.gov |
| NCT05152238 | ITP Registry and Accompanying Biospecimen Collection | — | Immune Thrombocytopenia | Recruiting | 2021-11-29 | 2027-04-01 | ClinicalTrials.gov |
| NCT05152238 | ITP Registry and Accompanying Biospecimen Collection | — | Immune Thrombocytopenia | Recruiting | 2021-11-29 | 2027-04-01 | ClinicalTrials.gov |
| NCT05357339 | Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock | Na | Sepsis, Severe | Completed | 2021-09-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT05357339 | Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock | Na | Sepsis, Severe | Completed | 2021-09-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT04722887 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different … | Phase1 | Alpha1-Antitrypsin Deficiency | Completed | 2021-08-13 | 2025-08-01 | ClinicalTrials.gov |
| NCT04722887 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different … | Phase1 | Alpha1-Antitrypsin Deficiency | Completed | 2021-08-13 | 2025-08-01 | ClinicalTrials.gov |
| NCT04899232 | Antithrombin III in Infectious Disease Caused by COVID-19 | Phase2 | Antithrombin III Deficiency | Terminated | 2021-07-06 | 2022-03-31 | ClinicalTrials.gov |
| NCT04899232 | Antithrombin III in Infectious Disease Caused by COVID-19 | Phase2 | Antithrombin III Deficiency | Terminated | 2021-07-06 | 2022-03-31 | ClinicalTrials.gov |
| NCT04847141 | A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infecte… | Phase3 | COVID-19 | Terminated | 2021-04-28 | 2021-12-27 | ClinicalTrials.gov |
| NCT04847141 | A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infecte… | Phase3 | COVID-19 | Terminated | 2021-04-28 | 2021-12-27 | ClinicalTrials.gov |
| NCT04547140 | Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor… | Phase2 | COVID-19 | Terminated | 2021-01-29 | 2022-01-28 | ClinicalTrials.gov |
| NCT04547140 | Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor… | Phase2 | COVID-19 | Terminated | 2021-01-29 | 2022-01-28 | ClinicalTrials.gov |
| NCT04055389 | Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients Wit… | Phase1 | Portal Vein Thrombosis | Withdrawn | 2021-01-01 | 2022-02-22 | ClinicalTrials.gov |
| NCT04055389 | Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients Wit… | Phase1 | Portal Vein Thrombosis | Withdrawn | 2021-01-01 | 2022-02-22 | ClinicalTrials.gov |
| NCT04566692 | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participa… | Phase4 | Primary Immunodeficiency | Completed | 2020-11-24 | 2022-07-25 | ClinicalTrials.gov |
| NCT04566692 | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participa… | Phase4 | Primary Immunodeficiency | Completed | 2020-11-24 | 2022-07-25 | ClinicalTrials.gov |
| NCT04621123 | Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patien… | Phase2 | SARS-CoV-2 Infection | Completed | 2020-11-10 | 2021-07-28 | ClinicalTrials.gov |
| NCT04621123 | Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patien… | Phase2 | SARS-CoV-2 Infection | Completed | 2020-11-10 | 2021-07-28 | ClinicalTrials.gov |
| NCT04356781 | Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous … | — | Multifocal Motor Neuropathy (MMN) | Completed | 2020-09-28 | 2024-12-30 | ClinicalTrials.gov |
| NCT04356781 | Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous … | — | Multifocal Motor Neuropathy (MMN) | Completed | 2020-09-28 | 2024-12-30 | ClinicalTrials.gov |
| NCT04621916 | Preventing Inhibitor Recurrence Indefinitely | Phase4 | Hemophilia A | Unknown | 2020-09-21 | 2025-04-20 | ClinicalTrials.gov |
| NCT04621916 | Preventing Inhibitor Recurrence Indefinitely | Phase4 | Hemophilia A | Unknown | 2020-09-21 | 2025-04-20 | ClinicalTrials.gov |
| NCT04480424 | Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globu… | Phase2 | COVID-19 | Completed | 2020-09-17 | 2021-10-25 | ClinicalTrials.gov |
| NCT04480424 | Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globu… | Phase2 | COVID-19 | Completed | 2020-09-17 | 2021-10-25 | ClinicalTrials.gov |
| NCT04561115 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Gl… | Phase3 | Primary Immunodeficiency | Completed | 2020-09-02 | 2022-03-28 | ClinicalTrials.gov |
| NCT04561115 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Gl… | Phase3 | Primary Immunodeficiency | Completed | 2020-09-02 | 2022-03-28 | ClinicalTrials.gov |
| NCT04495101 | Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects… | Phase2 | COVID-19 | Completed | 2020-07-29 | 2021-06-10 | ClinicalTrials.gov |
| NCT04495101 | Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects… | Phase2 | COVID-19 | Completed | 2020-07-29 | 2021-06-10 | ClinicalTrials.gov |
| NCT04432324 | Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Par… | Phase2 | COVID-19 | Completed | 2020-06-02 | 2021-03-03 | ClinicalTrials.gov |
| NCT04432324 | Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Par… | Phase2 | COVID-19 | Completed | 2020-06-02 | 2021-03-03 | ClinicalTrials.gov |
| NCT04547127 | A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated … | Phase2 | COVID-19 | Completed | 2020-04-29 | 2021-02-04 | ClinicalTrials.gov |
| NCT04547127 | A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated … | Phase2 | COVID-19 | Completed | 2020-04-29 | 2021-02-04 | ClinicalTrials.gov |
| NCT04213950 | Improving Adherence to Rabies PEP Guideline Recommendations | Na | Rabies | Completed | 2019-12-29 | 2020-12-23 | ClinicalTrials.gov |
| NCT04213950 | Improving Adherence to Rabies PEP Guideline Recommendations | Na | Rabies | Completed | 2019-12-29 | 2020-12-23 | ClinicalTrials.gov |
| NCT03814798 | Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatmen… | Phase3 | Primary Immunodeficiency | Withdrawn | 2019-12-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT03814798 | Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatmen… | Phase3 | Primary Immunodeficiency | Withdrawn | 2019-12-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT03869385 | Albumin Replacement Therapy in Septic Shock | Phase3 | Septic Shock | Terminated | 2019-10-21 | 2023-06-13 | ClinicalTrials.gov |
| NCT03869385 | Albumin Replacement Therapy in Septic Shock | Phase3 | Septic Shock | Terminated | 2019-10-21 | 2023-06-13 | ClinicalTrials.gov |
| NCT03778840 | Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab | — | Autoimmune Diseases | Completed | 2019-05-29 | 2022-05-31 | ClinicalTrials.gov |
| NCT03778840 | Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab | — | Autoimmune Diseases | Completed | 2019-05-29 | 2022-05-31 | ClinicalTrials.gov |
| NCT03702920 | Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasm… | Phase3 | Acute-On-Chronic Liver Failure | Terminated | 2019-02-21 | 2025-04-14 | ClinicalTrials.gov |
| NCT03702920 | Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasm… | Phase3 | Acute-On-Chronic Liver Failure | Terminated | 2019-02-21 | 2025-04-14 | ClinicalTrials.gov |
| NCT03461406 | A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemo… | Phase3 | Excessive Bleeding During Surgery | Completed | 2019-01-18 | 2022-05-20 | ClinicalTrials.gov |
| NCT03461406 | A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemo… | Phase3 | Excessive Bleeding During Surgery | Completed | 2019-01-18 | 2022-05-20 | ClinicalTrials.gov |
| NCT03749096 | Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positi… | Phase3 | Stiff-Person Syndrome | Withdrawn | 2018-12-07 | 2019-04-26 | ClinicalTrials.gov |
| NCT03749096 | Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positi… | Phase3 | Stiff-Person Syndrome | Withdrawn | 2018-12-07 | 2019-04-26 | ClinicalTrials.gov |
| NCT03919773 | IVIG (Gamunex-C) Treatment Study for POTS Subjects | Phase1 | Postural Tachycardia Syndrome | Completed | 2018-10-29 | 2023-12-01 | ClinicalTrials.gov |
| NCT03919773 | IVIG (Gamunex-C) Treatment Study for POTS Subjects | Phase1 | Postural Tachycardia Syndrome | Completed | 2018-10-29 | 2023-12-01 | ClinicalTrials.gov |
| NCT03451292 | Effects of Long-Term Administration of Human Albumin in Participants With Decom… | Phase3 | Decompensated Cirrhosis and Ascites | Completed | 2018-07-24 | 2024-05-21 | ClinicalTrials.gov |
| NCT03451292 | Effects of Long-Term Administration of Human Albumin in Participants With Decom… | Phase3 | Decompensated Cirrhosis and Ascites | Completed | 2018-07-24 | 2024-05-21 | ClinicalTrials.gov |
| NCT03585257 | HEAL STUDY (Hepatic Encephalopathy and Albumin Study) | Phase2 | Cirrhosis | Completed | 2018-06-20 | 2022-03-30 | ClinicalTrials.gov |
| NCT03585257 | HEAL STUDY (Hepatic Encephalopathy and Albumin Study) | Phase2 | Cirrhosis | Completed | 2018-06-20 | 2022-03-30 | ClinicalTrials.gov |
| NCT03095287 | Alphanate in Immune Tolerance Induction Therapy | Phase2 | Hemophilia A, Congenital | Terminated | 2018-01-03 | 2020-09-18 | ClinicalTrials.gov |
| NCT03095287 | Alphanate in Immune Tolerance Induction Therapy | Phase2 | Hemophilia A, Congenital | Terminated | 2018-01-03 | 2020-09-18 | ClinicalTrials.gov |
| NCT03351933 | Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) | Phase4 | Anti-Hepatitis A Antibody Levels in Heathy Subjects | Completed | 2017-10-31 | 2018-07-19 | ClinicalTrials.gov |
| NCT03351933 | Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) | Phase4 | Anti-Hepatitis A Antibody Levels in Heathy Subjects | Completed | 2017-10-31 | 2018-07-19 | ClinicalTrials.gov |
| NCT02915263 | The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropa… | Phase2 | Diabetes Complications | Terminated | 2017-09-11 | 2022-02-01 | ClinicalTrials.gov |
| NCT02915263 | The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropa… | Phase2 | Diabetes Complications | Terminated | 2017-09-11 | 2022-02-01 | ClinicalTrials.gov |
| NCT06666569 | Evaluation of the Effectiveness of Kits Promonitor-IFX/ADL and Promonitor-Anti-… | — | Crohn Disease and Ulcerative Colitis | Completed | 2017-01-16 | 2023-05-08 | ClinicalTrials.gov |
| NCT06666569 | Evaluation of the Effectiveness of Kits Promonitor-IFX/ADL and Promonitor-Anti-… | — | Crohn Disease and Ulcerative Colitis | Completed | 2017-01-16 | 2023-05-08 | ClinicalTrials.gov |
| NCT02690038 | Ig PRx in AECOPD: Pilot Study | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2016-09-01 | 2019-11-20 | ClinicalTrials.gov |
| NCT02690038 | Ig PRx in AECOPD: Pilot Study | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2016-09-01 | 2019-11-20 | ClinicalTrials.gov |
| NCT02872142 | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With A… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2016-08-29 | 2019-08-15 | ClinicalTrials.gov |
| NCT02872142 | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With A… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2016-08-29 | 2019-08-15 | ClinicalTrials.gov |
| NCT02870309 | Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human),… | Phase1 | Alpha1-Antitrypsin Deficiency | Completed | 2016-07-29 | 2017-03-15 | ClinicalTrials.gov |
| NCT02870348 | Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects Wi… | Phase1 | Alpha1-Antitrypsin Deficiency | Completed | 2016-07-29 | 2021-02-16 | ClinicalTrials.gov |
| NCT02870309 | Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human),… | Phase1 | Alpha1-Antitrypsin Deficiency | Completed | 2016-07-29 | 2017-03-15 | ClinicalTrials.gov |
| NCT02870348 | Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects Wi… | Phase1 | Alpha1-Antitrypsin Deficiency | Completed | 2016-07-29 | 2021-02-16 | ClinicalTrials.gov |
| NCT02281500 | Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB … | Phase1 | Congenital Afibrinogenemia | Completed | 2016-07-22 | 2019-11-11 | ClinicalTrials.gov |
| NCT02281500 | Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB … | Phase1 | Congenital Afibrinogenemia | Completed | 2016-07-22 | 2019-11-11 | ClinicalTrials.gov |
| NCT02796937 | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitry… | Phase3 | Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Enrolling_By_Invitation | 2016-07-01 | 2029-02-01 | ClinicalTrials.gov |
| NCT02796937 | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitry… | Phase3 | Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Enrolling_By_Invitation | 2016-07-01 | 2029-02-01 | ClinicalTrials.gov |
| NCT02806986 | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects Wi… | Phase3 | Primary Immunodeficiency | Completed | 2016-06-01 | 2019-05-15 | ClinicalTrials.gov |
| NCT02806986 | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects Wi… | Phase3 | Primary Immunodeficiency | Completed | 2016-06-01 | 2019-05-15 | ClinicalTrials.gov |
| NCT02697292 | IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy | Phase3 | Autoimmune Epilepsy | Terminated | 2016-02-01 | 2018-12-03 | ClinicalTrials.gov |
| NCT02697292 | IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy | Phase3 | Autoimmune Epilepsy | Terminated | 2016-02-01 | 2018-12-03 | ClinicalTrials.gov |
| NCT02604810 | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficien… | Phase3 | Primary Immunodeficiency | Completed | 2016-01-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02604810 | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficien… | Phase3 | Primary Immunodeficiency | Completed | 2016-01-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02547532 | Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency | — | Alpha-1 Antitrypsin Deficiency | Completed | 2015-09-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02547532 | Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency | — | Alpha-1 Antitrypsin Deficiency | Completed | 2015-09-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02473952 | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects W… | Phase2 | Myasthenia Gravis, Generalized | Completed | 2015-08-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02473952 | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects W… | Phase2 | Myasthenia Gravis, Generalized | Completed | 2015-08-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT04522635 | Fluid Mobilization in Hospitalized Patients With Acute Kidney Injury | Phase4 | Hypotension During Dialysis | Completed | 2015-06-03 | 2019-12-31 | ClinicalTrials.gov |
| NCT04522635 | Fluid Mobilization in Hospitalized Patients With Acute Kidney Injury | Phase4 | Hypotension During Dialysis | Completed | 2015-06-03 | 2019-12-31 | ClinicalTrials.gov |
| NCT02631174 | Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants … | Phase1 | Extracorporeal Membrane Oxygenation Complication | Completed | 2015-06-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02631174 | Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants … | Phase1 | Extracorporeal Membrane Oxygenation Complication | Completed | 2015-06-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With General… | Phase2 | Myasthenia Gravis | Completed | 2015-06-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With General… | Phase2 | Myasthenia Gravis | Completed | 2015-06-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia… | Phase3 | Myasthenia Gravis Exacerbations | Completed | 2015-03-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia… | Phase3 | Myasthenia Gravis Exacerbations | Completed | 2015-03-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02479802 | Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophi… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2014-11-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02479802 | Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophi… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2014-11-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02282527 | A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) i… | Phase2 | Alpha₁-Antitrypsin Deficiency | Completed | 2014-10-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02282527 | A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) i… | Phase2 | Alpha₁-Antitrypsin Deficiency | Completed | 2014-10-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02176863 | Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Fleboga… | Phase2 | Post-polio Syndrome | Terminated | 2014-09-23 | 2022-11-24 | ClinicalTrials.gov |
| NCT02176863 | Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Fleboga… | Phase2 | Post-polio Syndrome | Terminated | 2014-09-23 | 2022-11-24 | ClinicalTrials.gov |
| NCT02037555 | Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Un… | Phase2 | Cardiac Surgery | Completed | 2014-06-26 | 2018-01-25 | ClinicalTrials.gov |
| NCT02037555 | Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Un… | Phase2 | Cardiac Surgery | Completed | 2014-06-26 | 2018-01-25 | ClinicalTrials.gov |
| NCT02103114 | Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congeni… | Phase2 | ATIII Deficiency | Completed | 2014-06-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02103114 | Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congeni… | Phase2 | ATIII Deficiency | Completed | 2014-06-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02104245 | Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiect… | Phase3 | Non Cystic Fibrosis Bronchiectasis | Completed | 2014-05-28 | 2016-10-01 | ClinicalTrials.gov |
| NCT02104245 | Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiect… | Phase3 | Non Cystic Fibrosis Bronchiectasis | Completed | 2014-05-28 | 2016-10-01 | ClinicalTrials.gov |
| NCT02043379 | Post-bypass Prophylactic IVIG in Infants and Neonates | Na | Hypogammaglobulinemia | Completed | 2014-05-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02043379 | Post-bypass Prophylactic IVIG in Infants and Neonates | Na | Hypogammaglobulinemia | Completed | 2014-05-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01515007 | Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiect… | Phase3 | Non Cystic Fibrosis Bronchiectasis | Completed | 2014-03-31 | 2016-10-01 | ClinicalTrials.gov |
| NCT01515007 | Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiect… | Phase3 | Non Cystic Fibrosis Bronchiectasis | Completed | 2014-03-31 | 2016-10-01 | ClinicalTrials.gov |
| NCT02139657 | An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibod… | Phase1 | Rabies | Completed | 2014-03-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02093221 | Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-… | Phase2 | Type 1 Diabetes Mellitus | Terminated | 2014-03-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02093221 | Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-… | Phase2 | Type 1 Diabetes Mellitus | Terminated | 2014-03-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02139657 | An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibod… | Phase1 | Rabies | Completed | 2014-03-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02472665 | Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII C… | Phase4 | Von Willebrand Disease | Recruiting | 2013-12-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02014402 | Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemost… | Phase2 | Hemostasis | Completed | 2013-12-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02472665 | Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII C… | Phase4 | Von Willebrand Disease | Recruiting | 2013-12-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02014402 | Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemost… | Phase2 | Hemostasis | Completed | 2013-12-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01983241 | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (A… | Phase3 | Pulmonary Emphysema in Alpha-1 PI Deficiency | Active_Not_Recruiting | 2013-11-01 | 2027-01-01 | ClinicalTrials.gov |
| NCT01983241 | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (A… | Phase3 | Pulmonary Emphysema in Alpha-1 PI Deficiency | Active_Not_Recruiting | 2013-11-01 | 2027-01-01 | ClinicalTrials.gov |
| NCT01841619 | IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus | Early_Phase1 | Cutaneous Lupus Erythematosus | Completed | 2013-03-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01754480 | Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous … | Phase3 | Parenchymous Tissue Surgical Bleeding | Completed | 2013-03-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01841619 | IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus | Early_Phase1 | Cutaneous Lupus Erythematosus | Completed | 2013-03-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01754480 | Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous … | Phase3 | Parenchymous Tissue Surgical Bleeding | Completed | 2013-03-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01731938 | Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue O… | Phase3 | Soft Tissue Surgical Bleeding | Completed | 2012-11-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01731938 | Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue O… | Phase3 | Soft Tissue Surgical Bleeding | Completed | 2012-11-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01684410 | Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), H… | Phase2 | Cystic Fibrosis | Completed | 2012-08-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01662856 | Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis… | Phase3 | Vascular Surgical Bleeding | Completed | 2012-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01684410 | Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), H… | Phase2 | Cystic Fibrosis | Completed | 2012-08-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01662856 | Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis… | Phase3 | Vascular Surgical Bleeding | Completed | 2012-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01561053 | A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease | Phase2 | Alzheimer's Disease | Completed | 2012-04-19 | 2018-03-06 | ClinicalTrials.gov |
| NCT01561053 | A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease | Phase2 | Alzheimer's Disease | Completed | 2012-04-19 | 2018-03-06 | ClinicalTrials.gov |
| NCT01731691 | Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease | Phase2 | HIV Disease | Terminated | 2012-04-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01731691 | Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease | Phase2 | HIV Disease | Terminated | 2012-04-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02878733 | Albumin Administration and Outcomes in Cardiac Surgery | — | Thoracic Surgery | Completed | 2012-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT02878733 | Albumin Administration and Outcomes in Cardiac Surgery | — | Thoracic Surgery | Completed | 2012-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01465958 | Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatr… | Phase4 | Primary Immunodeficiency | Completed | 2011-11-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01465958 | Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatr… | Phase4 | Primary Immunodeficiency | Completed | 2011-11-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01201720 | Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory… | Na | Liver Cirrhosis | Completed | 2011-03-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01201720 | Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory… | Na | Liver Cirrhosis | Completed | 2011-03-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01222117 | A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion | Phase2 | Acute Peripheral Arterial Occlusion | Completed | 2010-12-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01222117 | A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion | Phase2 | Acute Peripheral Arterial Occlusion | Completed | 2010-12-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01213043 | Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Al… | Phase2 | Emphysema | Completed | 2010-11-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01213043 | Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Al… | Phase2 | Emphysema | Completed | 2010-11-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01131065 | Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurre… | Phase3 | Hepatitis B | Completed | 2010-07-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01131065 | Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurre… | Phase3 | Hepatitis B | Completed | 2010-07-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01380626 | Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Al… | Na | Chronic Obstructive Pulmonary Disease | Completed | 2010-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01380626 | Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Al… | Na | Chronic Obstructive Pulmonary Disease | Completed | 2010-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01051076 | Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced… | Na | Severe Hemophilia A | Completed | 2009-11-03 | 2020-10-21 | ClinicalTrials.gov |
| NCT01051076 | Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced… | Na | Severe Hemophilia A | Completed | 2009-11-03 | 2020-10-21 | ClinicalTrials.gov |
| NCT01014975 | A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle… | Phase1 | Acute Ischemic Stroke | Completed | 2009-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01014975 | A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle… | Phase1 | Acute Ischemic Stroke | Completed | 2009-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01051544 | Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients W… | Na | Severe Hemophilia A | Withdrawn | 2009-09-25 | 2020-06-25 | ClinicalTrials.gov |
| NCT01051544 | Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients W… | Na | Severe Hemophilia A | Withdrawn | 2009-09-25 | 2020-06-25 | ClinicalTrials.gov |
| NCT00968695 | Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and … | Phase4 | Cirrhosis | Completed | 2009-07-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00968695 | Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and … | Phase4 | Cirrhosis | Completed | 2009-07-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00823082 | Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass | Phase2 | Acquired Antithrombin III Deficiency | Completed | 2009-06-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00823082 | Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass | Phase2 | Acquired Antithrombin III Deficiency | Completed | 2009-06-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01757418 | Intravenous Gammaglobulin for Sickle Cell Pain Crises | Phase1 | Sickle Cell Disease | Completed | 2008-11-01 | 2024-12-18 | ClinicalTrials.gov |
| NCT01757418 | Intravenous Gammaglobulin for Sickle Cell Pain Crises | Phase1 | Sickle Cell Disease | Completed | 2008-11-01 | 2024-12-18 | ClinicalTrials.gov |
| NCT00511147 | IGIV Study for Chronic ITP Patients Ages 3-70 | Phase3 | Idiopathic Thrombocytopenic Purpura | Completed | 2008-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00511147 | IGIV Study for Chronic ITP Patients Ages 3-70 | Phase3 | Idiopathic Thrombocytopenic Purpura | Completed | 2008-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00634569 | Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects | Phase4 | Primary Immune Deficiency Disease | Completed | 2008-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00634569 | Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects | Phase4 | Primary Immune Deficiency Disease | Completed | 2008-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00684047 | Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to … | Phase2 | Target Bleeding Site During Peripheral Vascular Surgery | Completed | 2008-02-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00684047 | Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to … | Phase2 | Target Bleeding Site During Peripheral Vascular Surgery | Completed | 2008-02-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00699140 | Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura | Phase3 | Immune (Idiopathic) Thrombocytopenic Purpura | Completed | 2008-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00699140 | Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura | Phase3 | Immune (Idiopathic) Thrombocytopenic Purpura | Completed | 2008-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00555555 | Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients | Phase4 | Von Willebrand Disease | Active_Not_Recruiting | 2007-09-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT00555555 | Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients | Phase4 | Von Willebrand Disease | Active_Not_Recruiting | 2007-09-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT00742417 | Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide … | Phase2 | Alzheimer's Disease | Completed | 2007-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00742417 | Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide … | Phase2 | Alzheimer's Disease | Completed | 2007-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01179893 | Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis | Phase4 | Myasthenia Gravid | Completed | 2007-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00437671 | Tetanus Immunization in Subjects With No Immunization History or With Tetanus A… | Phase4 | Tetanus | Terminated | 2007-03-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00437671 | Tetanus Immunization in Subjects With No Immunization History or With Tetanus A… | Phase4 | Tetanus | Terminated | 2007-03-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT01179893 | Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis | Phase4 | Myasthenia Gravid | Completed | 2007-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00418483 | A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity … | Phase1 | Arterial Occlusive Diseases | Completed | 2007-03-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00418483 | A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity … | Phase1 | Arterial Occlusive Diseases | Completed | 2007-03-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00389324 | A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamun… | Phase2 | Immunologic Deficiency Syndrome | Completed | 2006-11-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00389324 | A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamun… | Phase2 | Immunologic Deficiency Syndrome | Completed | 2006-11-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00301366 | The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With A… | Phase3 | Alpha 1-Antitrypsin Deficiency | Completed | 2006-06-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00301366 | The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With A… | Phase3 | Alpha 1-Antitrypsin Deficiency | Completed | 2006-06-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00295061 | Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin… | Phase3 | Alpha 1-Antitrypsin Deficiency | Completed | 2006-05-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00295061 | Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin… | Phase3 | Alpha 1-Antitrypsin Deficiency | Completed | 2006-05-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00319228 | Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate | Phase2 | Antithrombin III Deficiency | Active_Not_Recruiting | 2006-01-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT00319228 | Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate | Phase2 | Antithrombin III Deficiency | Active_Not_Recruiting | 2006-01-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT03091751 | Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Heredit… | Phase2 | Hemophilia B | Completed | 2005-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT03091751 | Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Heredit… | Phase2 | Hemophilia B | Completed | 2005-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00115778 | Intravenous Immunoglobulin (IVIG) in Lung Transplantation | Phase2 | Hypogammaglobulinemia | Completed | 2005-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00115778 | Intravenous Immunoglobulin (IVIG) in Lung Transplantation | Phase2 | Hypogammaglobulinemia | Completed | 2005-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00417573 | Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infecti… | Phase2 | IgG Deficiency | Completed | 2004-12-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00417573 | Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infecti… | Phase2 | IgG Deficiency | Completed | 2004-12-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00220740 | Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyn… | Phase3 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Completed | 2004-04-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00220740 | Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyn… | Phase3 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Completed | 2004-04-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00220805 | Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degener… | Phase2 | Macular Degeneration | Completed | 2004-01-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00220805 | Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degener… | Phase2 | Macular Degeneration | Completed | 2004-01-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00263887 | Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) | Phase2 | Alpha 1-Antitrypsin Deficiency | Completed | 2003-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00486837 | Deposition of Inhaled Prolastin in Cystic Fibrosis Patients | Phase2 | Cystic Fibrosis | Completed | 2003-12-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00263887 | Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) | Phase2 | Alpha 1-Antitrypsin Deficiency | Completed | 2003-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00486837 | Deposition of Inhaled Prolastin in Cystic Fibrosis Patients | Phase2 | Cystic Fibrosis | Completed | 2003-12-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00220727 | Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP | Phase2 | Purpura, Thrombocytopenic, Idiopathic | Completed | 2003-07-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00220727 | Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP | Phase2 | Purpura, Thrombocytopenic, Idiopathic | Completed | 2003-07-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00323856 | Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia… | Phase4 | Severe Hemophilia A | Completed | 2003-04-08 | 2018-12-14 | ClinicalTrials.gov |
| NCT00323856 | Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia… | Phase4 | Severe Hemophilia A | Completed | 2003-04-08 | 2018-12-14 | ClinicalTrials.gov |
| NCT00220779 | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Scler… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2002-12-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00220779 | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Scler… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2002-12-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00220766 | Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficien… | Phase3 | Immunologic Deficiency Syndrome | Completed | 2002-08-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00220766 | Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficien… | Phase3 | Immunologic Deficiency Syndrome | Completed | 2002-08-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00606905 | Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurr… | Na | Miscarriage, Recurrent | Completed | 1999-11-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00606905 | Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurr… | Na | Miscarriage, Recurrent | Completed | 1999-11-01 | 2010-01-01 | ClinicalTrials.gov |
Total clinical trials: 232
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Manual Compression | Other | Phase PHASE2 | Target Bleeding Site During Peripheral Vascular Surgery | COMPLETED | NCT00684047 |
| FS Grifols | Other | Phase PHASE2 | Target Bleeding Site During Peripheral Vascular Surgery | COMPLETED | NCT00684047 |
| Manual Compression | Other | Phase PHASE2 | Target Bleeding Site During Peripheral Vascular Surgery | COMPLETED | NCT00684047 |
| FS Grifols | Other | Phase PHASE2 | Target Bleeding Site During Peripheral Vascular Surgery | COMPLETED | NCT00684047 |
| Manual Compression | Other | Phase PHASE2 | Target Bleeding Site During Peripheral Vascular Surgery | COMPLETED | NCT00684047 |
| FS Grifols | Other | Phase PHASE2 | Target Bleeding Site During Peripheral Vascular Surgery | COMPLETED | NCT00684047 |
| IGIV3I Grifols | Other | Phase PHASE3 | Immune (Idiopathic) Thrombocytopenic Purpura | COMPLETED | NCT00699140 |
| IGIV3I Grifols | Other | Phase PHASE3 | Immune (Idiopathic) Thrombocytopenic Purpura | COMPLETED | NCT00699140 |
| IGIV3I Grifols | Other | Phase PHASE3 | Immune (Idiopathic) Thrombocytopenic Purpura | COMPLETED | NCT00699140 |
| Hepatitis B immune globulin | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT01131065 |
| Hepatitis B immune globulin | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT01131065 |
| Hepatitis B immune globulin | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT01131065 |
| Control | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00742417 |
| Albutein 5% | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00742417 |
| Control | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00742417 |
| Albutein 5% | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00742417 |
| Albumin | Other | Preclinical | Thoracic Surgery | COMPLETED | NCT02878733 |
| Albumin | Other | Preclinical | Thoracic Surgery | COMPLETED | NCT02878733 |
| Antithrombin III | Other | Phase PHASE2 | Acquired Antithrombin III Deficiency | COMPLETED | NCT00823082 |
| Antithrombin III | Other | Phase PHASE2 | Acquired Antithrombin III Deficiency | COMPLETED | NCT00823082 |
| Antithrombin III | Other | Phase PHASE2 | Acquired Antithrombin III Deficiency | COMPLETED | NCT00823082 |
| Flebogamma 5% DIF | Other | Phase PHASE4 | Primary Immune Deficiency Disease | COMPLETED | NCT00634569 |
| Flebogamma 5% DIF | Other | Phase PHASE4 | Primary Immune Deficiency Disease | COMPLETED | NCT00634569 |
| Flebogamma 5% DIF | Other | Phase PHASE4 | Primary Immune Deficiency Disease | COMPLETED | NCT00634569 |
| Surgicel® | Other | Phase PHASE3 | Parenchymous Tissue Surgical Bleeding | COMPLETED | NCT01754480 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Parenchymous Tissue Surgical Bleeding | COMPLETED | NCT01754480 |
| Surgicel® | Other | Phase PHASE3 | Parenchymous Tissue Surgical Bleeding | COMPLETED | NCT01754480 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Parenchymous Tissue Surgical Bleeding | COMPLETED | NCT01754480 |
| Surgicel® | Other | Phase PHASE3 | Parenchymous Tissue Surgical Bleeding | COMPLETED | NCT01754480 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Parenchymous Tissue Surgical Bleeding | COMPLETED | NCT01754480 |
| Surgicel® | Other | Phase PHASE3 | Parenchymous Tissue Surgical Bleeding | COMPLETED | NCT01754480 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Parenchymous Tissue Surgical Bleeding | COMPLETED | NCT01754480 |
| Surgicel® | Other | Phase PHASE3 | Soft Tissue Surgical Bleeding | COMPLETED | NCT01731938 |
| Fibrin Sealant (FS) Grifols | Other | Phase PHASE3 | Soft Tissue Surgical Bleeding | COMPLETED | NCT01731938 |
| Surgicel® | Other | Phase PHASE3 | Soft Tissue Surgical Bleeding | COMPLETED | NCT01731938 |
| Fibrin Sealant (FS) Grifols | Other | Phase PHASE3 | Soft Tissue Surgical Bleeding | COMPLETED | NCT01731938 |
| Manual Compression | Other | Phase PHASE3 | Vascular Surgical Bleeding | COMPLETED | NCT01662856 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Vascular Surgical Bleeding | COMPLETED | NCT01662856 |
| Manual Compression | Other | Phase PHASE3 | Vascular Surgical Bleeding | COMPLETED | NCT01662856 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Vascular Surgical Bleeding | COMPLETED | NCT01662856 |
| Manual Compression | Other | Phase PHASE3 | Vascular Surgical Bleeding | COMPLETED | NCT01662856 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Vascular Surgical Bleeding | COMPLETED | NCT01662856 |
| IGIV3I Grifols 10% | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00511147 |
| IGIV3I Grifols 10% | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00511147 |
| IGIV3I Grifols 10% | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00511147 |
| Bovine thrombin | Other | Phase PHASE2 | Hemostasis | COMPLETED | NCT02014402 |
| Human thrombin | Other | Phase PHASE2 | Hemostasis | COMPLETED | NCT02014402 |
| Bovine thrombin | Other | Phase PHASE2 | Hemostasis | COMPLETED | NCT02014402 |
| Human thrombin | Other | Phase PHASE2 | Hemostasis | COMPLETED | NCT02014402 |
| Bovine thrombin | Other | Phase PHASE2 | Hemostasis | COMPLETED | NCT02014402 |
| Human thrombin | Other | Phase PHASE2 | Hemostasis | COMPLETED | NCT02014402 |
| BeneFIX | Other | Phase PHASE2 | Hemophilia B | COMPLETED | NCT03091751 |
| BeneFIX | Other | Phase PHASE2 | Hemophilia B | COMPLETED | NCT03091751 |
| BeneFIX | Other | Phase PHASE2 | Hemophilia B | COMPLETED | NCT03091751 |
| collection of sputum | Other | Preclinical | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT02547532 |
| collection of sputum | Other | Preclinical | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT02547532 |
| Antithrombin III | Other | Phase PHASE1 | Extracorporeal Membrane Oxygenation Complication | COMPLETED | NCT02631174 |
| Antithrombin III | Other | Phase PHASE1 | Extracorporeal Membrane Oxygenation Complication | COMPLETED | NCT02631174 |
| Plasma exchange with albumin | Other | Approved | Liver Cirrhosis | COMPLETED | NCT01201720 |
| Plasma exchange with albumin | Other | Approved | Liver Cirrhosis | COMPLETED | NCT01201720 |
| Plasma exchange with albumin | Other | Approved | Liver Cirrhosis | COMPLETED | NCT01201720 |
| Placebos | Other | Phase PHASE3 | Stiff-Person Syndrome | WITHDRAWN | NCT03749096 |
| Intravenous Immunoglobulins, Human | Other | Phase PHASE3 | Stiff-Person Syndrome | WITHDRAWN | NCT03749096 |
| Placebos | Other | Phase PHASE3 | Stiff-Person Syndrome | WITHDRAWN | NCT03749096 |
| Intravenous Immunoglobulins, Human | Other | Phase PHASE3 | Stiff-Person Syndrome | WITHDRAWN | NCT03749096 |
| Placebos | Other | Phase PHASE3 | Stiff-Person Syndrome | WITHDRAWN | NCT03749096 |
| Intravenous Immunoglobulins, Human | Other | Phase PHASE3 | Stiff-Person Syndrome | WITHDRAWN | NCT03749096 |
| Albumin | Other | Phase PHASE4 | Cirrhosis | COMPLETED | NCT00968695 |
| Albumin | Other | Phase PHASE4 | Cirrhosis | COMPLETED | NCT00968695 |
| Albumin | Other | Phase PHASE4 | Cirrhosis | COMPLETED | NCT00968695 |
| Immunoglobulin | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01561053 |
| Albumin 20% | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01561053 |
| Albumin 5% | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01561053 |
| Immunoglobulin | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01561053 |
| Albumin 20% | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01561053 |
| Albumin 5% | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01561053 |
| Placebo | Other | Phase PHASE2 | ATIII Deficiency | COMPLETED | NCT02103114 |
| Anti-thrombin III | Other | Phase PHASE2 | ATIII Deficiency | COMPLETED | NCT02103114 |
| Placebo | Other | Phase PHASE2 | ATIII Deficiency | COMPLETED | NCT02103114 |
| Anti-thrombin III | Other | Phase PHASE2 | ATIII Deficiency | COMPLETED | NCT02103114 |
| Normal Saline | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Placebos | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Intravenous Immunoglobulin | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Normal Saline | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Placebos | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Intravenous Immunoglobulin | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Normal Saline | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Placebos | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Intravenous Immunoglobulin | Other | Phase PHASE3 | Autoimmune Epilepsy | TERMINATED | NCT02697292 |
| Albumin | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02479802 |
| Albumin | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02479802 |
| Albumin | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02479802 |
| (100 ml of Albumin 25%) | Other | Phase PHASE4 | Hypotension During Dialysis | COMPLETED | NCT04522635 |
| (100 ml of Albumin 25%) | Other | Phase PHASE4 | Hypotension During Dialysis | COMPLETED | NCT04522635 |
| (100 ml of Albumin 25%) | Other | Phase PHASE4 | Hypotension During Dialysis | COMPLETED | NCT04522635 |
| Placebos | Other | Phase PHASE2 | HIV Disease | TERMINATED | NCT01731691 |
| α1 Proteinase Inhibitor | Other | Phase PHASE2 | HIV Disease | TERMINATED | NCT01731691 |
| Placebos | Other | Phase PHASE2 | HIV Disease | TERMINATED | NCT01731691 |
| α1 Proteinase Inhibitor | Other | Phase PHASE2 | HIV Disease | TERMINATED | NCT01731691 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04547127 |
| Convalescent anti-SARS-CoV-2 MBT Plasma | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04547127 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04547127 |
| Convalescent anti-SARS-CoV-2 MBT Plasma | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04547127 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04547127 |
| Convalescent anti-SARS-CoV-2 MBT Plasma | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04547127 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04547127 |
| Convalescent anti-SARS-CoV-2 MBT Plasma | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04547127 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04432324 |
| Intravenous Immune Globulin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04432324 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04432324 |
| Intravenous Immune Globulin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04432324 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04432324 |
| Intravenous Immune Globulin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04432324 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04495101 |
| Prolastin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04495101 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04495101 |
| Prolastin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04495101 |
| Standard Medical Treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04495101 |
| Prolastin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04495101 |
| Rabies PEP quality improvement bundle | Other | Approved | Rabies | COMPLETED | NCT04213950 |
| Rabies PEP quality improvement bundle | Other | Approved | Rabies | COMPLETED | NCT04213950 |
| Control Group | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT04621123 |
| Convalescent anti-SARS-CoV-2 MBT plasma | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT04621123 |
| Control Group | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT04621123 |
| Convalescent anti-SARS-CoV-2 MBT plasma | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT04621123 |
| Placebo | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03585257 |
| 25% IV albumin | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03585257 |
| Placebo | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03585257 |
| 25% IV albumin | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03585257 |
| Placebo | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03585257 |
| 25% IV albumin | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03585257 |
| Antithrombin III | Other | Phase PHASE2 | Antithrombin III Deficiency | TERMINATED | NCT04899232 |
| Antithrombin III | Other | Phase PHASE2 | Antithrombin III Deficiency | TERMINATED | NCT04899232 |
| Antithrombin III | Other | Phase PHASE2 | Antithrombin III Deficiency | TERMINATED | NCT04899232 |
| Albumin | Other | Phase PHASE2 | Immune-Mediated Necrotizing Myopathy | WITHDRAWN | NCT04450654 |
| Gamunex-C | Other | Phase PHASE2 | Immune-Mediated Necrotizing Myopathy | WITHDRAWN | NCT04450654 |
| EVICEL | Other | Phase PHASE3 | Excessive Bleeding During Surgery | COMPLETED | NCT03461406 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Excessive Bleeding During Surgery | COMPLETED | NCT03461406 |
| EVICEL | Other | Phase PHASE3 | Excessive Bleeding During Surgery | COMPLETED | NCT03461406 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Excessive Bleeding During Surgery | COMPLETED | NCT03461406 |
| EVICEL | Other | Phase PHASE3 | Excessive Bleeding During Surgery | COMPLETED | NCT03461406 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Excessive Bleeding During Surgery | COMPLETED | NCT03461406 |
| EVICEL | Other | Phase PHASE3 | Excessive Bleeding During Surgery | COMPLETED | NCT03461406 |
| Fibrin Sealant Grifols | Other | Phase PHASE3 | Excessive Bleeding During Surgery | COMPLETED | NCT03461406 |
| Alphanate SD/HT | Other | Phase PHASE4 | Von Willebrand Disease | ACTIVE_NOT_RECRUITING | NCT00555555 |
| Plasma-derived AT-III concentrate | Other | Phase PHASE2 | Antithrombin III Deficiency | ACTIVE_NOT_RECRUITING | NCT00319228 |
| Emicizumab | Other | Phase PHASE4 | Hemophilia A | ACTIVE_NOT_RECRUITING | NCT04621916 |
| FVIII | Other | Phase PHASE4 | Hemophilia A | ACTIVE_NOT_RECRUITING | NCT04621916 |
| FIB Grifols | Other | Phase PHASE3 | Congenital Afibrinogenemia | WITHDRAWN | NCT04636268 |
| FIB Grifols | Other | Phase PHASE3 | Congenital Afibrinogenemia | WITHDRAWN | NCT04636268 |
| FIB Grifols | Other | Phase PHASE3 | Congenital Afibrinogenemia | WITHDRAWN | NCT04636268 |
| FIB Grifols | Other | Phase PHASE3 | Congenital Afibrinogenemia | WITHDRAWN | NCT04636268 |
| 0.9% Sodium Chloride | Other | Phase PHASE2 | Diabetes Complications | TERMINATED | NCT02915263 |
| IGIV-C | Other | Phase PHASE2 | Diabetes Complications | TERMINATED | NCT02915263 |
| Albumin | Other | Phase PHASE1 | Postural Tachycardia Syndrome | COMPLETED | NCT03919773 |
| IVIG | Other | Phase PHASE1 | Postural Tachycardia Syndrome | COMPLETED | NCT03919773 |
| Albumin | Other | Phase PHASE1 | Postural Tachycardia Syndrome | COMPLETED | NCT03919773 |
| IVIG | Other | Phase PHASE1 | Postural Tachycardia Syndrome | COMPLETED | NCT03919773 |
| Crystalloid | Other | Approved | Sepsis, Severe | COMPLETED | NCT05357339 |
| 20% Albumin | Other | Approved | Sepsis, Severe | COMPLETED | NCT05357339 |
| Crystalloid | Other | Approved | Sepsis, Severe | COMPLETED | NCT05357339 |
| 20% Albumin | Other | Approved | Sepsis, Severe | COMPLETED | NCT05357339 |
| Albutein® 200 g/L or Plasbumin® 20 | Other | Phase PHASE3 | Septic Shock | TERMINATED | NCT03869385 |
| Albutein® 200 g/L or Plasbumin® 20 | Other | Phase PHASE3 | Septic Shock | TERMINATED | NCT03869385 |
| Albutein® 200 g/L or Plasbumin® 20 | Other | Phase PHASE3 | Septic Shock | TERMINATED | NCT03869385 |
| Use of the test for treatment optimization | Drug | Preclinical | Crohn Disease and Ulcerative Colitis | COMPLETED | NCT06666569 |
| Use of the test for treatment optimization | Drug | Preclinical | Crohn Disease and Ulcerative Colitis | COMPLETED | NCT06666569 |
| Use of the test for treatment optimization | Drug | Preclinical | Crohn Disease and Ulcerative Colitis | COMPLETED | NCT06666569 |
| Alphanate SD/HT | Other | Phase PHASE4 | Severe Hemophilia A | COMPLETED | NCT00323856 |
| Alphanate SD/HT | Other | Phase PHASE4 | Severe Hemophilia A | COMPLETED | NCT00323856 |
| Albumin Infusion | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06052176 |
| Normal Saline (0.9% NaCl) | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06812390 |
| Albumin infusion (25% albumin) | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06812390 |
| Normal Saline (0.9% NaCl) | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06812390 |
| Albumin infusion (25% albumin) | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06812390 |
| Gamunex-C, 10% Injectable Solution | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | RECRUITING | NCT07582432 |
| Normal Saline (0.9% NaCl) | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06812390 |
| Albumin infusion (25% albumin) | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06812390 |
| Normal Saline (0.9% NaCl) | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06812390 |
| Albumin infusion (25% albumin) | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06812390 |
| Placebo | Other | Phase PHASE2 | Trauma Injury | ENROLLING_BY_INVITATION | NCT05794165 |
| Thrombate infusion | Other | Phase PHASE2 | Trauma Injury | ENROLLING_BY_INVITATION | NCT05794165 |
| Placebo | Other | Phase PHASE2 | Trauma Injury | ENROLLING_BY_INVITATION | NCT05794165 |
| Thrombate infusion | Other | Phase PHASE2 | Trauma Injury | ENROLLING_BY_INVITATION | NCT05794165 |
| Placebo | Other | Phase PHASE2 | Trauma Injury | ENROLLING_BY_INVITATION | NCT05794165 |
| Thrombate infusion | Other | Phase PHASE2 | Trauma Injury | ENROLLING_BY_INVITATION | NCT05794165 |
| Placebo | Other | Phase PHASE2 | Trauma Injury | ENROLLING_BY_INVITATION | NCT05794165 |
| Thrombate infusion | Other | Phase PHASE2 | Trauma Injury | ENROLLING_BY_INVITATION | NCT05794165 |
| Blood Sampling | Other | Preclinical | Alpha 1-antitrypsin Deficiency (AATD) | RECRUITING | NCT07152834 |
| Blood Sampling | Other | Preclinical | Alpha 1-antitrypsin Deficiency (AATD) | RECRUITING | NCT07152834 |
| Human rabies immune globulin 300 IU/mL | Other | Preclinical | Rabies | TERMINATED | NCT05382650 |
| Human rabies immune globulin 300 IU/mL | Other | Preclinical | Rabies | TERMINATED | NCT05382650 |
| Placebo | Other | Phase PHASE2 | Post-polio Syndrome | TERMINATED | NCT02176863 |
| Flebogamma® 5% DIF | Other | Phase PHASE2 | Post-polio Syndrome | TERMINATED | NCT02176863 |
| Placebo | Other | Phase PHASE2 | Post-polio Syndrome | TERMINATED | NCT02176863 |
| Flebogamma® 5% DIF | Other | Phase PHASE2 | Post-polio Syndrome | TERMINATED | NCT02176863 |
| Placebo Comparator | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07264517 |
| GRF312 5% | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07264517 |
| Placebo Comparator | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07264517 |
| GRF312 5% | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07264517 |
| Placebo Comparator | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07264517 |
| GRF312 5% | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07264517 |
| Albumin Infusion | Other | Phase PHASE2 | Cirrhosis | RECRUITING | NCT06052176 |
| Gamunex-C, 10% Injectable Solution | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | RECRUITING | NCT07582432 |
Total products: 204